CQ10 for CMT->to Sally

[Guest guest]

Hi Sally,

Unfortunately we only have the abstract in our archives. I tried to

get in to the Journal cited and couldn't. Also asked a librarian-

friend to see if she could get in. Will post the " whole enchilada " if

I get it.

Now, I was searching under " child neuromuscular disease treatment

with antixodants " and the following abstract came up. It mentions CMT

in it. It says the participants in the study were from 7 years old to

69. Also, this study was published a good 10 years ago. Most all

significant research is done on adults - I'd really like to see

researchers branch out more to the pediatric arena on this subject

and many more.

I was on a quest going back to circa 1965 looking for info on CMT and

antioxidant use/benefits. I got lost in the 1990's - more on another

day! I am sitting here thinking and wondering out loud again why when

I was a child/teen that antioxidants weren't given to me, like E or

C. But then as a teen my neurologist had me taking the Theragran

vitamin, so I guess that had enough E and C in it to help me. It's

only been since the late 80's in the newsletter that I've heard of

COQ10.

I also found a couple of references to C0Q10 on 's website -

just type in COQ10 in the search box. One is a general CMT page but

mentions COQ10, the other is about Mark Tarnapolosky's " cocktail "

research that includes CoQ10. Again, I think both are written for the

adult CMT population. Hope this is helpful. ~ Gretchen

-------------

Biochim Biophys Acta. 1995 May 24;1271(1):281-6.

Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on

muscular dystrophies and neurogenic atrophies.

Folkers K, Simonsen R.

Institute for Biomedical Research, University of Texas at Austin

78705, USA.

Coenzyme Q10 (vitamin Q10) is biosynthesized in the human body and is

functional in bioenergetics, anti-oxidation reactions, and in growth

control, etc. It is indispensable to health and survival. The first

double-blind trial was with twelve patients, ranging from 7-69 years

of age, having diseases including the Duchenne, Becker, and the limb-

girdle dystrophies, myotonic dystrophy. Charcot-Marie-Tooth disease,

and the Welander disease. The control coenzyme Q10 (CoQ10) blood

level was low and ranged from 0.5-0.84 microgram/ml. They were

treated for three months with 100 mg daily of CoQ10 and a matching

placebo. The second double-blind trial was similar with fifteen

patients having the same categories of disease. Since cardiac disease

is established to be associated with these muscle diseases, cardiac

function was blindly monitored, and not one mistake was made in

assigning CoQ10 and placebo to the patients in both trials.

Definitely improved physical performance was recorded. In retrospect,

a dosage of 100 mg was too low although effective and safe. Patients

suffering from these muscle dystrophies and the like, should be

treated with vitamin Q10 indefinitely.